The Supreme Court unanimously rejected a lawsuit involving the key abortion medication mifepristone last week, but legal experts say the issue is hardly settled.

The case, brought to the court by the anti-abortion organization Alliance for Hippocratic Medicine, aimed to limit access to medication abortion by questioning the Food and Drug Administration’s regulatory power. Experts say the ruling does nothing to change access to mifepristone and represents just one battle in a long war against the procedure.

“This decision from the Supreme Court means that nothing changes,” said David S. Cohen, a professor at the Drexel University School of Law, specializing in abortion law. “It just means this lawsuit was not properly brought, but it changes nothing in the world.”

Supreme Court judges ruled that the plaintiffs lacked standing to challenge the FDA’s decision to approve and regulate mifepristone. Standing is a legal merit that requires a plaintiff to have been directly impacted by the defendant, or to have been injured in some way. Because the plaintiffs have not been prescribed and do not prescribe the drug, the case was stayed and thus dismissed.

Advertise with us

“The overall struggle is far from over, it’s just that this decision doesn’t limit mifepristone access,” said Mary Ziegler, Martin Luther King Jr. Professor of Law at University of California Davis School of Law, specializing in abortion.

The court questioned the plaintiffs’ arguments against the FDA, deeming the arguments “complicated” and full of “causation theories” and stating that those theories were inadequate to establish standing.

Read More

It’s quite possible that new plaintiffs could bring a similar case forward in an effort to curb mifepristone, and that the courts could interpret the law differently in the future, said Mr. Cohen and Ms. Ziegler. The attorney in charge of the lawsuit, the Alliance Defending Freedom, previously helped overturn Roe v. Wade in 2022 and has a track record of winning Supreme Court cases.

“They will in fact find other plaintiffs,” said Ms. Ziegler.

Without the protection of Roe v. Wade, abortion access has become a patchwork across the nation. To date, 14 states have effectively banned the procedure, with an additional seven states placing restrictions.

Advertise with us

These bans haven’t erased abortion access altogether. A May 14 #WeCount survey, conducted by the Society for Family Planning, found that 8,000 women a month who lived in states with restrictions or bans received abortion pills through telehealth prescriptions between October and December 2023.

Anti-abortion groups are concerned about mifepristone, in part, because medication abortion provides an option for people who live in areas without abortion clinics, and access in red states depends on the flow of these pills, said Ms. Ziegler.

“It’s very hard to stop pills,” said Mr. Cohen.

Abortion is currently legal in Pennsylvania up to 23 weeks and 6 days gestation, and Gov. Josh Shapiro has stated his intentions to protect the procedure while he remains in office.

Local health care provider Allegheny Health Network said in an email statement that it “fully support[s] the FDA’s rigorous process to determine the efficacy and safety of all medications, including mifepristone, and the recent Supreme Court decision allows our network to maintain full access to a comprehensive set of evidence-based reproductive medicine therapies for our patients.”

Advertise with us

But the foreseeable future of abortion access may lie in the hands of FDA, Department of Justice and Department of Health and Human Services appointees — which could change depending on who becomes president, Mr. Cohen explained.

Conservatives’ plan, said Ms. Ziegler, may in fact be to secure the White House and appoint new leaders to these agencies, changing mifepristone access from the inside. A Trump administration may also begin enforcing The Comstock Act, a 19th century law that prohibited the mailing of “lewd” or “obscene” matter, which could be interpreted to mean abortion medication or materials to perform them.

“This case does confirm what everyone knows: that this is a political issue,” said Mr. Cohen.

If a federal abortion ban is enacted or the Comstock Act is enforced, states not previously impacted will begin to feel the heat, said Ms. Ziegler. Recent ballot initiatives and additional state protections may not matter.

There’s some evidence that states are stockpiling mifepristone in preparation for November, said Mr. Cohen, and there’s been an increase in interest for advanced provision, or the prescribing of mifepristone to have on-hand before a pregnancy occurs.

Advertise with us

“Nothing will be settled, nothing will be protected, everything will be contested,” Mr. Cohen said. “That’s just the state of abortion.”

Hanna Webster: hwebster@post-gazette.com